Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET

Peer review reports

Original Submission
20 Jun 2023	Submitted	Original manuscript
15 Oct 2023	Reviewed	Reviewer Report - crispin musicha
19 Oct 2023	Reviewed	Reviewer Report - Lexy Sorrell
23 Nov 2023	Author responded	Author comments - Simron Singh
Resubmission - Version 2
23 Nov 2023	Submitted	Manuscript version 2
Publishing
24 Nov 2023	Editorially accepted
16 Jan 2024	Article published	10.1186/s13063-023-07834-8

Back to article page